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SUMMARY 
Objective 
De novo mutations of SCN8A, encoding the voltage-gated sodium channel Nav1.6, have been 
associated with a severe infant-onset epileptic encephalopathy. Individuals with SCN8A 
encephalopathy have a mean age of seizure onset of 4-5 months, with multiple seizure types that 
are often refractory to treatment with available drugs. Anecdotal reports suggest that high-dose 
phenytoin is effective for some patients, but there are associated adverse effects and potential 
toxicity. Functional characterization of several SCN8A encephalopathy variants has shown that 
elevated persistent sodium current is one of several common biophysical defects. Therefore, 
specifically targeting elevated persistent current may be a useful therapeutic strategy in some 
cases.  
Methods 
The novel sodium channel modulator GS967 has greater preference for persistent versus peak 
current and nearly ten-fold greater potency than phenytoin. We evaluated the therapeutic effect 
of GS967 in the Scn8a-N1768D/+ mouse model carrying an SCN8A patient mutation that results 
in elevated persistent sodium current. We also performed patch clamp recordings to assess the 
effect of GS967 on peak and persistent sodium current and excitability in hippocampal neurons 
from Scn8a-N1768D/+ mice. 
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Results 
GS967 potently blocked persistent sodium current without affecting peak current, normalized 
action potential morphology, and attenuated excitability in neurons from heterozygous Scn8a-
N1768D/+ mice. Acute treatment with GS967 provided dose-dependent protection against MES-
induced seizures in Scn8a-N1768D/+ and wild-type mice. Chronic treatment of Scn8a-
N1768D/+ mice with GS967 resulted in lower seizure burden and complete protection from 
seizure-associated lethality observed in untreated Scn8a-N1768D/+ mice. Protection was 
achieved at a chronic dose that did not cause overt behavioral toxicity or sedation. 
Significance 
Persistent sodium current modulators like GS967 may be an effective precision targeting strategy 
for SCN8A encephalopathy and other functionally similar channelopathies when elevated 
persistent sodium current is the primary dysfunction. 
 
Keywords:  epilepsy; voltage-gated sodium channel; pharmacology; mouse model; epileptic 
encephalopathy  
Key Points  
• GS967 potently suppressed persistent sodium current in acutely dissociated neurons and 
hyperexcitability in slices from heterozygous Scn8a-N1768D/+ mice • Acute treatment with GS967 dose-dependently protected both Scn8a-N1768D/+ and 
wild-type mice against MES-induced seizures • Chronic GS967 treatment was associated with significantly lower spontaneous seizure 
burden and completely protected Scn8a-N1768D/+ mice from seizure-associated lethality • Chronic GS967 did not cause overt behavioral toxicity or sedation in wild-type mice at 
the effective anticonvulsant dose 
INTRODUCTION 
Epilepsy is a common neurological disorder with a lifetime incidence of 1 in 26 1. Mutations in 
genes encoding neuronal voltage-gated sodium channels have been implicated in several types of 
human epilepsy, including epileptic encephalopathies 2. These are severe epilepsies with co-
occurring cognitive, behavioral, and neurological deficits due to the combined effect of seizure 
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activity and the underlying mutation 3. In recent years, over 150 cases of epileptic 
encephalopathy have been associated with de novo mutations in SCN8A, encoding the Nav1.6 
voltage-gated sodium channel pore-forming (alpha) subunit. The clinical phenotype begins in the 
first year of life with pleiomorphic seizures that are difficult to control, delayed cognitive 
development and motor impairment 4. SCN8A encephalopathy is also associated with an elevated 
risk for sudden unexpected death in epilepsy (SUDEP), making seizure control a high priority 5; 6
 
. 
The first report of SCN8A encephalopathy described a female proband with multiple seizure 
types, intellectual disability, developmental delay, and motor impairment 2. She succumbed to 
SUDEP at 15 years of age. Whole genome sequencing of the family quartet identified the 
heterozygous, de novo mutation SCN8A p.Asn1768Asp (N1768D) 7. Electrophysiological 
recording of sodium currents in ND7/23 cells expressing the mutant channel revealed a large 
persistent sodium current as the primary biophysical defect, as well as incomplete channel 
inactivation and a shift in the voltage dependence of steady-state fast inactivation 7. Introduction 
of the N1768D mutation into the murine Scn8a gene resulted in a mouse model that recapitulates 
many features of the human syndrome 8; 9. Specifically, heterozygous Scn8aN1768D/+ (Scn8aD/+) 
mice exhibit spontaneous seizures, ataxia, cardiac arrhythmia, and premature death, although the 
age of seizure onset at 2-4 months of age is late relative to the SCN8A-N1768D proband. 
Homozygous Scn8aN1768D/N1768D (Scn8aD/D) mice exhibit these features with earlier onset and 
accelerated progression. Similar to recordings in heterologous expression systems, neurons from 
Scn8aD/+ mice have elevated persistent current and higher spontaneous firing rate compared to 
wild-type (WT) neurons 7; 10
 
. The mouse model enables preclinical evaluation of potential anti-
convulsant treatments for SCN8A encephalopathy. 
Several types of biophysical defects have been documented for variants associated with SCN8A 
encephalopathy. Targeting persistent sodium current, one of the common primary biophysical 
defects in this disorder, may provide an effective precision therapeutic approach. Reports have 
described patients achieving seizure control with carbamazepine, oxcarbazepine, valproic acid, 
and most notably, high-dose phenytoin 11-16. Phenytoin is a state-dependent sodium channel 
blocker with a small preference (~10%) for persistent current over peak current 17. However, 
high dose phenytoin has significant safety concerns due to saturable metabolism and risk for 
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phenytoin poisoning 18-21. GS-458967 (GS967) is a novel sodium channel modulator specifically 
developed to inhibit persistent sodium current, with a 42-fold preference for persistent versus 
peak current inhibition 22. Our previous studies demonstrated that acute application of GS967 to 
hippocampal neurons did not affect the current-voltage relationship or voltage dependence of 
activation, but induced a hyperpolarized shift of steady-state channel inactivation and slowed 
both recovery from fast inactivation and onset of slow inactivation 23. GS967 has also been 
reported to have strong use-dependent block 24
 
. 
GS967 was previously tested in the Scn2aQ54 mouse model with epilepsy caused by elevated 
persistent sodium current in hippocampal neurons 25. Acute application of GS967 to neurons 
isolated from untreated Scn2aQ54 mice reduced persistent sodium current and spontaneous firing, 
while GS967 treatment of Scn2aQ54 mice reduced seizure burden and improved survival. 
Considering the etiological similarities between Scn2aQ54 and Scn8aD/+ mice, we hypothesized 
that treatment with GS967 may have a therapeutic benefit in the Scn8aD/+ and Scn8aD/D
 
 mice.  
In the current study, we tested the effect of GS967 on persistent sodium current and action 
potential firing in neurons, as well as seizure susceptibility, spontaneous seizures and survival of 
Scn8aD/+
 
 mice. We report that GS967 suppresses persistent sodium current and excitability in 
neurons ex vivo, and protects against seizures and premature lethality in vivo, supporting 
targeting of persistent sodium current as a potential therapeutic strategy for this disorder. 
METHODS 
Mice 
Scn8aem1Mm mice were generated using TALEN technology and previously characterized 8; 9. The 
line was made congenic by continuous backcrossing to C3HeB/FeJ wild-type (WT) mice (Stock 
# 000658, Jackson Laboratory, Bar Harbor, ME) for more than 10 generations. Mice were 
genotyped by PCR of tail biopsy DNA as previously described 8. Heterozygous experimental 
mice were obtained by breeding Scn8aD/+ males with C3HeB/FeJ females. Homozygous 
experimental mice were generated by breeding Scn8aD/+ males with Scn8aD/+ females. Mice 
were housed in Specific Pathogen Free barrier facility with a 14/10 hour light/dark cycle and 
access to food and water ad libitum. Animal studies were approved by the Northwestern 
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University and the University of Virginia Animal Care and Use Committees in accordance with 
the NIH Guide for the Care and Use of Animals. Principles outlined in the ARRIVE (Animal 
Research: Reporting of in vivo Experiments) and Basel declaration (including the 3R concept) 
were considered in experimental design. Both male and female mice were used in all 
experiments. 
 
Drugs 
GS967 was provided by Gilead Sciences (Foster City, CA, USA) or purchased from Cayman 
Chemical (Ann Arbor, MI, USA). Phenytoin sodium solution was manufactured by West-Ward 
Pharmaceuticals (Eatontown, NJ) and obtained from Patterson Veterinary Supply (Greeley, CO). 
Phenytoin for electrophysiology experiments was obtained from Sigma Aldrich (St. Louis, MO). 
Drug solutions for electrophysiology experiments were prepared in DMSO. For acute 
administration to mice in MES experiments, GS967 was solubilized in vegetable oil, and 
phenytoin sodium solution was diluted with 0.5% methyl cellulose in water. Vehicle control 
mice were administered either vegetable oil or 0.5% methyl cellulose in water. For chronic 
administration studies, mice were fed Purina 5001 rodent chow compounded with GS967 (8 mg 
per kg of chow; Research Diets, New Brunswick, NJ) 23; 25. The estimated dose was 1.5 
mg/kg/day based on average daily consumption of 190 grams of chow per kg of body weight 
(http://www.researchdiets.com/resource-center-page/typical-food-intake). Previous studies 
showed that chronic treatment with this dose resulted in GS967 plasma and brain concentrations 
of 1.0 ± 0.08 μM and 1.7 ± 0.1 μM, respectively 23
 
. Chronic treatment with GS967 at 1.5 
mg/kg/day did not cause overt adverse neurobehavioral or sedating effects in WT C3HeB/FeJ at 
5-7 weeks of treatment (Supplemental Fig. S1). 
Isolated Neuron Preparation and Electrophysiology Recording 
Neurons were acutely isolated from untreated Scn8aD/+ mice and WT littermates between 30 and 
35 days of age. Hippocampal neurons were isolated as previously described 25. Whole-cell 
voltage clamp experiments of acutely isolated pyramidal neurons were performed at room 
temperature using previously described methods 26; 27. External recording solution contained (in 
mM): 20 NaCl, 100 N-methyl-D-glucamine, 10 HEPES, 1.8 CaCl2·2H2O, 2 MgCl2·6H2O, and 
20 tetraethylammonium chloride with pH adjusted to 7.35 with HCl and osmolarity adjusted to 
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310 mOsmol/kg with sucrose. Internal solution consisted of (in mM):5 NaF, 105 CsF, 20 CsCl, 2 
EGTA, and 10 HEPES with pH adjusted to 7.35 with CsOH and osmolarity adjusted to 280 
mOsmol/kg with sucrose. All whole-cell voltage clamp recordings utilized a holding potential of 
-120 mV. Voltage gated sodium currents were recorded in the absence and presence of 500 nM 
TTX, and analyzed following offline digital subtraction, as previously described 26; 27
 
. Persistent 
current was measured utilizing a 200 ms depolarizing step. Mean current in the final 10 ms was 
normalized to peak transient current. Statistical comparisons were made using Student’s t-test or 
one-way ANOVA followed by Tukey’s post hoc and p < 0.05 was considered statistically 
significant. 
Brain Slice Preparation and Electrophysiology Recording 
Brain slices were prepared from WT and Scn8aD/+ mice (> 8 weeks of age) using a Leica 
VT1200 vibratome as previously described 10.CA1 pyramidal neurons were visually identified 
using infrared video microscopy (Hamamatsu) with a Zeiss Axioscope microscope. Whole-cell 
current-clamp recordings were performed as previously described 10. During recordings, slices 
were held in a small chamber and superfused with oxygenated ACSF (in mM: 125 NaCl, 2.5 
KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 0.5 L-ascorbic acid, 10 glucose, 25 NaHCO3
Action potentials (APs) were evoked using a depolarizing current injection step of 400 pA. To 
standardize across neurons, resting membrane potentials were maintained at -70 mV by injection 
of DC current. Only depolarizing events that consisted of a single observable peak initiating 
from threshold and had an upstroke velocity >150 mV/ms were considered as APs. Early after-
depolarizing events (EADs) were identified as spikelets that occurred during the repolarizing 
phases of the initial AP and had slower upstroke velocities (>15 mV/ms), longer widths and 
depolarized thresholds. Input resistance was calculated using a -20 pA hyperpolarizing current 
injection step. The approximate rheobase for each cell was defined as the highest current 
injection step that did not evoke any APs. AP duration (APD) was defined as the width of the AP 
at the half way voltage between threshold and AP peak and was measured for the first AP 
, and 2 
sodium pyruvate (osmolarity 300-312 mOsm/L) at ~28°C at a rate of 1-2 mL/min. Intracellular 
recording solution containing (in mM): 120 K-gluconate, 10 NaCl, 2 MgCl2, 0.5 K2EGTA, 10 
HEPES, 4 Na2ATP, 0.3 NaGTP, and pH was adjusted to 7.2 with KOH (osmolarity 270-290 
mOsmol/L) 
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elicited during a 400 pA current injection. In order to measure intrinsic membrane and AP 
properties, a ramp of depolarizing current (0-400 pA) was injected into each neuron over a 4 sec 
time period. Threshold was identified as the membrane potential at which the upstroke velocity 
was 5% of its maximum 28
 
. AP amplitude, upstroke velocity and downstroke velocity were 
calculated using the first evoked AP during the current ramp. Amplitude was defined as the 
difference between threshold and AP peak, while upstroke velocity and downstroke velocity 
were defined as the maximum and minimum slope of the evoked AP, respectively. 
Maximal Electroshock 
At 4 weeks of age, mice were assigned to treatment groups by block randomization and received 
an intraperitoneal injection of test compound (PHT or GS967) or their respective vehicle in a 
volume of 10 ml/kg body weight two hours prior to testing. Maximal electroshock (MES) tests 
were conducted at the previously determined time-to-peak effect for GS967 and phenytoin 25. 
Corneal electroshock was delivered using a pulse generator set at a frequency of 60 Hz and 0.5 
ms pulse width (Ugo Basile) with shock duration 0.2 s and current 20 mA (120 mC) for Scn8aD/+ 
and 0.4 s, and 60 mA (720 mC) for WT mice. Mice were scored for the presence or absence of 
full tonic hindlimb extension (hindlimbs at a 180° angle to torso) occurring within 5 seconds of 
the shock. EC50
 
 values were determined from dose-response curves generated and compared 
with GraphPad Prism software. 
Survival 
At 6 weeks of age, heterozygous Scn8aD/+ mice were assigned to either GS967 or control 
treatment groups by block randomization. Mice in the GS967 treatment group were provided 
chow containing GS967 (8 mg per kg of chow; Research Diets, New Brunswick, NJ). The 
estimated dose was 1.5 mg/kg/day based on average consumption of 4 grams of chow per day. 
Previous studies established that this dose results in plasma levels of ~1 μM 23; 25
Homozygous Scn8a
. Survival was 
monitored up to 9 months of age by performing census checks 3-4 days per week.  
D/D
 mice were generated by crossing Scn8aD/+ males and Scn8aD/+ females. 
When the resulting offspring were 5 days of age, the lactating dam was either maintained on 
control chow or switched to GS967 chow. Previous studies showed that GS967 passes freely to 
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nursing pups resulting a plasma concentration of ~1 μM 23. Survival of the Scn8aD/D
Survival was assessed with Kaplan-Meier analysis and compared between groups using the 
Mantel Cox Log Rank test with p < 0.05 considered statistically significant. 
 pups was 
monitored by performing census checks 6-7 days per week.  
 
Video-Electroencephalography (EEG) 
At 6 weeks of age, Scn8aD/+ mice and WT littermates were assigned to either GS967 or control 
treatment groups by block randomization. At age 70-80 days, mice were anesthetized with 
isoflurane and fitted with a pre-fabricated headmount (Pinnacle Technology). Following at least 
48 hours of recovery, mice underwent continuous video-EEG recording for 5-13 days. 
Additional days of continuous video-only recording were obtained (range 3-26 days). Digitized 
EEG data was acquired and analyzed with Sirenia software (Pinnacle Technology). Epileptiform 
activity was scored offline by a blinded observer to identify electrographic seizures and 
behavioral correlates. The behavioral component of seizures scored by video-only were 
indistinguishable from those scored by epileptiform activity. Seizure frequencies were calculated 
for each individual animal and compared between treated and untreated Scn8aD/+
 
 mice using a 
Mann-Whitney test with p < 0.05 considered statistically significant. 
CNS Safety Screen 
At 6 weeks of age, WT C3HeB/FeJ mice were assigned to either GS967 or control treatment 
groups by block randomization and commenced treatment. At 11-13 weeks of age, mice were 
tested on three assays on consecutive days using a modified Irwin screen (day 1) 29, open field 
test (day 2) and rotarod test (day 3). All testing was conducted between 9:00am and 1:00pm. For 
the open field assay, mice were placed in a new environment and tracked for 10 minutes 
(Limelight software, Actimetrics). Mice were scored on total distance traveled. For the rotarod 
assay, mice underwent a training trial (4 rpm) and then three test trials with acceleration from 4-
40 rpm (Panlab/Harvard Apparatus). Trials were separated by 15 minutes of rest. Latency to fall 
was recorded for the three trials and averaged. Parametric data were compared using Student’s t-
tests and non-parametric data were compared using Mann-Whitney U-test, with p < 0.05 was 
considered statistically significant. No significant sex differences were observed, so groups were 
collapsed across sex. 
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RESULTS 
GS967 suppresses persistent current in hippocampal neurons from Scn8aD/+
Using whole-cell voltage clamp recording, we measured persistent sodium current in acutely 
isolated hippocampal pyramidal neurons from postnatal day 30 to 35 (P30-P35) Scn8a
 mice 
D/+
 mice. 
Persistent current was assessed as tetrodotoxin-sensitive current following a 200 ms 
depolarization. In untreated neurons from Scn8aD/+ mice, persistent current was equal to 1.7 ± 
0.3 % of peak current (n = 8) (Fig. 1A, black trace). The magnitude of persistent current is lower 
than previous reports due to differences in cell type and recording conditions 10
GS967 suppresses early afterdepolarizations (EADs) and reduces neuronal excitability in 
CA1 pyramidal neurons from Scn8a
. To assess the 
ability of either GS967 or phenytoin to selectively inhibit persistent sodium current, neurons 
were acutely treated with drug concentrations approximating the therapeutic free drug 
concentration in mouse brain, 200 nM GS967 or 4 µM phenytoin. In the presence of GS967, 
persistent current was more than ten-fold lower than in the absence of compound (0.12 ± 0.06% 
of peak current, n = 7; p < 0.001, one-way ANOVA and Tukey’s post hoc). In the presence of 
phenytoin, persistent current was approximately two-fold lower than drug-free conditions (0.94 ± 
0.09% of peak current, n=6; p < 0.04). Thus, GS967 was more potent than phenytoin in 
suppressing persistent current mediated by the mutant channel (p < 0.04) (Fig. 1A-B). 
Importantly, neither compound significantly altered peak sodium current under these conditions 
(Fig. 1C). 
D/+
AP waveforms from Scn8a
 mice 
D/+
 mice CA1 pyramidal neurons exhibited prominent EADs that were 
evident during the repolarization phase of APs (Fig. 2A-C), in agreement with previous studies 
30
. These abnormal waveforms were not observed in WT controls (Fig. 2D). Addition of GS967 
had a profound effect on EADs, reducing their number by 41% at 500 nM and 50% at 1 µM 
GS967 (Fig 2B-C). GS967 had no effect on AP firing frequencies from either Scn8aD/+ or WT 
(+/+) neurons (Fig 2Ai-Di). Analysis of AP parameters revealed differences between Scn8aD/+ 
and WT neurons (Table S1). GS967 (1 µM) decreased AP amplitude and upstroke velocity in 
both Scn8aD/+ and WT neurons. AP thresholds were also depolarized in Scn8aD/+ neurons, but 
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not WT (Fig 2E, Table S1). APDs were not changed (Table S1). These findings demonstrate that 
GS967 can modulate intrinsic hyper-excitability of CA1 neurons from Scn8aD/+ 
GS967 is more potent than phenytoin for seizure protection in the MES assay 
mice. 
We assessed acute anticonvulsant activity of GS967 and phenytoin using the maximal 
electroshock (MES) paradigm in Scn8aD/+ mice and WT littermates. The electroconvulsive 
stimulus (ECS) required to induce maximal hindlimb extension in >95% of mice (ECS95) was 
determined for both genotypes. Scn8aD/+ mice required a stimulus of 120 mC compared to 720 
mC for WT mice. Varying doses of GS967 or phenytoin were administered two hours prior to 
MES induction using the genotype-appropriate ECS95. Both GS967 and phenytoin provided 
dose-dependent protection against MES-induced tonic hindlimb seizures, with GS967 exhibiting 
greater potency. Scn8aD/+ mice were protected from maximal hindlimb extension with a 
calculated EC50 of 1.2 ± 0.2 mg/kg for GS967 and 5.3 ± 0.7 mg/kg for phenytoin (Fig. 3A). 
Similar results were found in WT mice with an EC50
Chronic GS967 treatment prolongs survival of Scn8a
 of 0.7 ± 0.2 mg/kg for GS967 and 6.9 ± 0.5 
mg/kg for phenytoin (Fig. 3B).  
D/+
Survival of Scn8a
 mice 
D/+
 mice is limited, with fewer than 50% of mice surviving to 6 months of age 
9
. To determine whether chronic treatment with GS967 would extend survival, Scn8aD/+ mice 
were fed chow containing GS967 (estimated dose 1.5 mg/kg/day) beginning at 6 weeks and 
continuing until 6 months of age. This dose was previously shown to be anticonvulsant in 
Scn2aQ54 and Scn1a+/- mouse models 23; 25 and does not produce any signs of behavioral toxicity 
or sedation (Supplementary Fig. S1). Treatment with GS967 beginning at 6 weeks and 
continuing to 6 months of age completely rescued premature lethality of Scn8aD/+
The phenotype of homozygous Scn8a
 mice, with 
100% of GS967-treated mice (n = 32) surviving to 6 months of age, compared with only 24% of 
untreated mice (7/29) (p < 0.001, LogRank Mantel-Cox). Removal of the GS967 chow at 6 
months of age resulted in rapid loss of protection and 65% of the previously treated mice died 
within the following 3 months (Fig. 4A). Loss of GS967 benefit following withdrawal suggests 
that it acts primarily as an anticonvulsant rather than a disease-modifying treatment.  
D/D
 mice is much more severe than heterozygous Scn8aD/+ 
mice or heterozygous patients. Scn8aD/D mice exhibit 100% lethality by 21 days of age 9. 
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Treatment of Scn8aD/D
GS967 reduces spontaneous seizures in Scn8a
 mice, achieved by feeding nursing dams GS967 beginning at P5, 
extended survival by one week (p < 0.001, LogRank Mantel-Cox) (Fig. 4B). 
D/+
Previous reports showed that Scn8a
 mice  
D/+
 mice have spontaneous seizures with onset at 2 to 4 
months of age, followed by death within a few days of seizure onset 9; 31. To evaluate the effect of 
GS967 on spontaneous seizures, mice were continuously observed with a combination of video-
electroencephalography (EEG) monitoring and continuous video monitoring for several hundred 
hours (Fig. 5; Supplemental Figure S2). Only 2/7 GS treated mice experienced any seizures 
during the time of monitoring, compared with 7/7 untreated mice (Table 1). All recorded seizures 
in Scn8aD/+ mice initiated with a tonic phase and culminated in full tonic hindlimb extension, 
with the angle of hindlimbs to the torso ≥180°. Several of the untreated mice exhibited seizure 
clustering, with days of seizure freedom separating periods of high seizure frequency 
(Supplemental Figure S2). Untreated Scn8aD/+ mice also exhibited seizures with multiple tonic to 
tonic-clonic transitions. In contrast, seizures in the GS967-treated Scn8aD/+ mice had a single 
tonic phase that terminated with post-ictal suppression. Combined analysis of video-EEG and 
video monitoring showed that Scn8aD/+
 
 mice treated with GS967 had significantly lower seizure 
frequency, with 0.3 ± 0.2 seizures/24-hours in GS967-treated compared with 1.6 ± 0.4 
seizures/24-hours in untreated mice (p < 0.004, Fig. 5C, Table 1). No seizures were observed in 
WT littermate mice (Table 1). These data demonstrate that GS967 has a potent anti-seizure effect 
in a mouse model of SCN8A encephalopathy. 
DISCUSSION 
In this study, we demonstrated that GS967 provided significant reduction in spontaneous seizure 
burden and improved survival in the Scn8aD/+ epilepsy model. We also demonstrated that GS967 
provided protection from acute MES-induced seizures in both Scn8aD/+
 
 and WT mice. 
GS967 is a potent blocker of persistent current arising from the Scn8a-N1768D mutation 
We and others previously reported that GS967 is a potent inhibitor of persistent sodium current 
22; 24; 32-34
, with 9-fold greater potency than phenytoin in hippocampal pyramidal neurons from 
Scn2aQ54 mice 25. Consistent with these reports, acute application of 200 nM GS967 or 4 μM 
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phenytoin to acutely dissociated hippocampal neurons isolated from Scn8aD/+ mice resulted in 
inhibition of persistent sodium current without significantly affecting peak current. Consistent 
with this, acute application of GS967 to hippocampal slices from Scn8aD/+
 
 mice resulted in 
normalization of intrinsic excitability in CA1 neurons. 
Anticonvulsant activity of GS967 
To assess anticonvulsant activity of GS967, we first established the dose-response relationship of 
acutely administered GS967 for MES-induced seizures, using the conventional anticonvulsant 
phenytoin as a comparator. We demonstrated that GS967 provided dose-dependent protection 
against MES-induced seizures with ~5-10-fold greater potency than phenytoin in both WT and 
Scn8aD/+ mice. Chronic administration of GS967 was associated with a dramatically lower 
spontaneous seizure frequency and prevented lethality at a dose that did not cause overt 
neurobehavioral toxicity or sedation. GS967 treatment provided complete protection in 
heterozygous Scn8aD/+ mice that have the same genotype as the N1768D proband with SCN8A 
encephalopathy, resulting from a heterozygous de novo mutation. Even in the severely affected 
homozygous Scn8aD/D mice, GS967 extended survival from 3 weeks to 4 weeks of age. Similar 
to individuals with SCN8A encephalopathy, Scn8aD/+ mice exhibit tonic and/or tonic-clonic 
seizures that may occur in clusters. Video-EEG monitoring showed that untreated Scn8aD/+ mice 
often exhibit prolonged seizures with multiple tonic to tonic-clonic transitions. GS967-treated 
mice were completely protected from these multi-phase events and exhibited only isolated 
seizures with a single tonic phase. These observations suggest that GS967 may reduce the extent 
of ictal events, in addition to reducing seizure frequency. These effects are likely to contribute to 
the survival benefit, because poor seizure control and frequent, prolonged generalized tonic-
clonic seizures are major risk factors for SUDEP 35. GS967 was originally developed as an 
antiarrhythmic compound 22; 24; 32; 33, and may also have a direct effect on the heart. This effect 
may contribute to the protection against sudden death, since Scn8aD/+ mice have hyperexcitable 
cardiomyocytes and episodes of bradycardia observed in electrocardiograms 36
Although we demonstrate dramatic improvement in seizure burden and survival in Scn8a
. 
D/+
 mice 
treated with GS967, there are some limitations of our preclinical study that warrant 
consideration. First, GS967 treatment was commenced prior to seizure onset and it is not known 
if commencing treatment after fulminant onset would provide the same level of protection. 
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Second, the age of seizure onset in the mouse Scn8aD/+ model is later than that observed in the 
proband, suggesting that the mouse model does not directly phenocopy the human case. Third, 
SCN8A encephalopathy includes mutations that result in a variety of NaV
Beyond Scn8a
1.6 dysfunction ranging 
from gain-of-function defects, including but not limited to persistent sodium current, to loss-of-
function defects. This suggests that GS967 would not necessarily be broadly effective in all cases 
of SCN8A encephalopathy, but rather that knowledge of the specific channel dysfunction may 
provide additional information for rational therapy choice. 
D/+
 mice, GS967 was previously shown to reduce seizure burden and improve 
survival in Scn2aQ54 mice, which share the biophysical defect of elevated persistent sodium 
current 25; 37. GS967 was also shown to have a protective effect in the Scn1a+/- Dravet mouse 
model that has reduced activity in inhibitory neurons and elevated excitability in excitatory 
neurons mice 23; 26. However, there is no evidence for alteration of persistent current in this 
model, suggesting that GS967 can have protective benefit in a genetic model with an alternate 
underlying mechanism. Furthermore, we demonstrated here and in a previous report that GS967 
has potent anti-seizure activity in the MES assay in WT mice 25
 
, supporting potentially broader 
applicability of GS967 in epilepsies with divergent etiologies.  
Conclusions 
We demonstrate that targeting of a specific biophysical defect in Nav1.6 gating observed with 
some SCN8A patient mutations is an effective antiepileptic treatment strategy in Scn8aD/+
 
 mice. 
This supports a precision medicine approach to SCN8A encephalopathy, and suggests that 
defining the biophysical defect may provide valuable information to guide therapy. Moreover, 
results from acute MES studies and other genetic models, suggest that suppression of Nav1.6 
activity may also be a general therapeutic approach relevant to other genetic and non-genetic 
epilepsies.  
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FIGURE LEGENDS  
Figure 1. GS967 inhibits persistent sodium current in acutely isolated hippocampal pyramidal 
neurons from Scn8aD/+ mice. A, Representative traces showing persistent sodium current of 
untreated (black), GS967 treated (red), and phenytoin (PHT) treated (blue) neurons from 
Scn8aD/+ mice. B&C, Summary data of persistent sodium current (B) and current-voltage 
relationship for peak sodium current (C) for untreated (black symbols, n = 8), phenytoin treated 
(blue symbols, n = 6), and GS967 treated (red symbols, n = 7) neurons from Scn8aD/+
 
 mice. 
Open symbols represent individual cells, while closed symbols represent mean ± S.E.M. 
Statistical comparison were performed using one-way ANOVA followed by Tukey’s post-test. * 
represent statistical difference compared to untreated cells for phenytoin (p < 0.04 and GS967 (p 
< 0.001) treated cells. 
Figure 2. GS967 suppresses early afterdepolarizations and reduces intrinsic excitability of CA1 
pyramidal neurons from Scn8aD/+ mice. A-D, upper panel traces show representative APs 
evoked using a 400 pA depolarizing current injection step. Black, before GS967; red, after 
GS967 at (A) 200 nM (n = 8 from 3 mice), (B) 500 nM (n = 12 from 3 mice), and (C) 1 µM (n = 
13 from 7 mice). (D) WT (+/+), n= 11 from 3 mice. Lower panels, representative EADs and (Ai-
Di) bar/scatter plots showing effect of GS967 on APs and EADs evoked by a current injection 
step of 400 pA. (E) Representative trace for slow current ramp recorded from a CA1 pyramidal 
neuron before (black) and after (red) GS967 at 500 nM. Values are mean ± SEM. Significant 
results were determined using paired student's t-test with alpha set to 0.05. 
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Figure 3. GS967 protects against MES-induced seizures in Scn8aD/+ and wild-type (WT) mice 
with greater potency than phenytoin (PHT). Mice were pre-treated with test compound or vehicle 
and then received an electroconvulsive stimulus determined to reliably elicit seizures with 
maximal hindlimb extension in Scn8aD/+ (120 mC) or WT (720 mC) mice. A, Dose response 
curves of GS967 and phenytoin for MES seizures in Scn8aD/+ mice. The curve for GS967 is 
significantly shifted compared to phenytoin and the estimated EC50 for GS967 and phenytoin are 
1.1 ± 0.23 mg/kg and 5.33 ± 0.69 mg/kg, respectively (p < 0.001, n = 5-24, Student’s t-test). 
Symbols represent mean ± S.E.M. B, Dose response curves of GS967 and phenytoin for MES 
seizures in WT mice. The curve is also significantly shifted and the estimated EC50 
 
for GS967 
and phenytoin are 0.70 ± 0.22 mg/kg and 6.93 ± 0.45 mg/kg, respectively (p < 0.001, n = 6-26, 
Student’s t-test).  
Figure 4. Treatment with GS967 significantly prolongs survival in heterozygous and 
homozygous mutants. A, Kaplan-Meier survival curves comparing untreated and GS967-treated 
Scn8aD/+ mice. Treatment was started at 6 weeks of age (first dashed line) and was withdrawn at 
6 months (second dashed line). Survival was significantly different between treatment groups (p 
< 0.001; n = 29-32; Mantel Cox Log Rank test). B, Kaplan-Meier survival curves comparing 
untreated and GS967-treated Scn8aD/D
 
 mice. Treatment was started at 5 days of age (dashed 
line). Survival difference between treatment groups was significant (p < 0.001; n=6-8; Mantel 
Cox Log Rank test). 
Figure 5. Treatment with GS967 reduces the spontaneous seizure frequency in Scn8aD/+ mice. 
A, Schematic representation of timeline for treatment, surgery, and monitoring of mice. B, 
Representative EEG trace of an electrographic seizure in a Scn8aD/+ mouse. Channel 1 indicates 
left anterior to right anterior, Channel 2 indicates right anterior to left posterior. C, Seizure 
frequency was significantly lower in Scn8aD/+ 
 
mice treated with GS967 compared to untreated (p 
< 0.004; Mann-Whitney test; n = 7 per group). Symbols represent mean ± S.E.M. Au
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Table 1. Extended spontaneous seizure monitoring in Scn8aD/+
Treatment 
 and WT mice treated chronically 
with 1.5 mg/kg/day GS967 and untreated controls. 
Genotype n  Total # of 
hours 
monitored  
Avg # of 
hours 
monitored 
per animal 
± SEM 
(range) 
Total # 
of 
seizures 
% of 
seizures 
with 
multiple 
transitions 
Avg Seizure 
Frequency* 
(seizures 
per 24 
hours ± 
SEM) 
Fraction 
of mice 
with 
observed 
seizures 
GS967 Scn8a 7 D/+ 1699 243 ± 52 
(62-361) 
9 0 % 0.3 ± 0.2 2 / 7 
Untreated Scn8a 7  D/+ 2189 313 ± 94 
(68-614) 
137 46 % 1.6 ± 0.4 
 
7 / 7 
GS967 WT 3 628 209 ± 172 
(102-408) 
0 0 % 0 ± 0.0 0 / 3 
Untreated WT 2 96 48 ± 24 
(24-72) 
0 0 % 0 ± 0.0 0 / 2 
*Calculated by averaging individual seizure frequencies within each group. 
 
Supplemental Information 
 
Supplemental Figure S1. Chronic treatment with GS967 for 5-7 weeks does not result in signs 
of neurobehavioral toxicity or sedation. At 6 weeks of age, WT C3HeB/FeJ mice were assigned 
to 1.5 mg/kg/day GS967 or control chow groups by block randomization. At 11-13 weeks of age, 
mice were tested in three assays on consecutive days. A, Modified Irwin screen conducted on 
day 1 showed no significant difference in neurobehavioral scores between GS967-treated and 
untreated control mice (p > 0.05; n = 16-18; Mann-Whitney test). Symbols represent mean ± 
S.E.M. B, Overall locomotor activity in an open-field was measured on day 2. GS967-treated 
mice showed a small, but significant increase in total distance traveled relative to untreated 
control mice, indicated by asterisk (p < 0.05; n=13-16; Student’s t-test). C, On day 3 latency to 
fall from an accelerating rotarod showed no significant difference between GS967-treated and 
untreated control mice (p > 0.05; n = 16-17; Student’s t-test). 
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Supplemental Figure S2. Seizure diary plot for Scn8aD/+
 
 mice undergoing continuous 
monitoring. Each line represents a single subject (1-7, Untreated; 9-15, GS967-treated). Black 
tick marks indicate a seizure event with a single tonic phase and orange tick marks represent 
seizure events with multiple tonic to tonic-clonic transitions. Recorded deaths are shown as 
triangles. Grey brackets indicate start and stop of continuous monitoring. Occasional brief 
monitoring gaps that account for <0.2% of total time (for husbandry or technical tasks) are 
omitted for presentation clarity. Seizure counts and calculated frequencies are summarized in 
Table 1. 
Supplemental Table S1. Effects of GS967 on action potential (AP) parameters of WT and 
Scn8aD/+ CA1 neurons 
Au
th
or
 M
an
us
cr
ip
t
epi_14196_f1.tif
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
epi_14196_f2.tif
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
epi_14196_f3.tif
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
epi_14196_f4.tif
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
epi_14196_f5.tif
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
